Opinions differ on what patients are more likely to respond to.
Which of the following is more likely to influence a patient’s willingness to be treated with a biosimilar?
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.